Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s share price fell 4.6% during trading on Thursday . The company traded as low as $5.80 and last traded at $5.86, with a volume of 217,658 shares traded. The stock had previously closed at $6.14.

A number of research firms have recently commented on RPTP. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a report on Sunday, June 12th. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Friday, May 6th. Zacks Investment Research downgraded Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. Cowen and Company reiterated a “buy” rating and issued a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Sunday, April 17th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $11.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Tuesday, April 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $11.00.

The stock’s market cap is $505.01 million. The firm’s 50 day moving average price is $5.62 and its 200-day moving average price is $4.76.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). During the same quarter in the prior year, the firm posted ($0.24) earnings per share. The company had revenue of $27.47 million for the quarter, compared to analysts’ expectations of $27.17 million. Raptor Pharmaceutical Corp.’s quarterly revenue was up 34.3% on a year-over-year basis. Analysts forecast that Raptor Pharmaceutical Corp. will post ($0.99) EPS for the current fiscal year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its position in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 as of its most recent filing with the SEC.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.